Shoulder Replacement

The company grew in the high single digits in 3Q21, led by shoulder implant sales and recent acquisitions.

The company's orthopedic business grew only 2% organically in 3Q21 due to the Delta variant and hospital staffing shortages.

The company reported more than 35% growth in the first half of 2021 with gains driven by new products and an expanded salesforce.

The company benefitted from improving COVID conditions in 2Q21 and remains on course to achieve both short and long-term strategic goals.

In 2Q21 the company made impressive gains in sports medicine and extremities but has yet to find a path to above-market growth in knees.

In 2Q21, the company drove incremental gains over 2019 as markets continue to recover. DJO expects to be a $1 billion recon player by 2026.

Although the company finished 2Q21 ahead of its 2019 performance, its knee franchise was double digits for that same comparison period.

While the company's organic revenue declined slightly due to pandemic-related restrictions, its integration of Wright Medical goes smoothly.

The company's Mako robotic system and new customizable ASC plan helped offset losses from COVID-related procedure cancelations.

More than a year after announcing its intention to acquire Wright Medical for $5.4 billion, Stryker today completed the purchase.

While the company improved sequentially, weakness in emerging markets, and significant knee replacement losses hobbled its recovery.

The company's orthopedic sales declined -49% in 2Q20 but recovered significantly from -80% declines in April. Integra expects improvement through 2H20.

The company exited June down just -3% in its joint replacement business and expects sequential improvements to continue through 2020 and into 2021.

The 1H18 performance of companies that make up ~80% of the joint reconstruction market achieved 4.1% growth vs. 1H17. These companies posted 2.4% growth in 1H17 vs. 1H16. Here is a look at past activity and future predictions for hip, knee and extremities.